Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Jefferies Downgrades Tenet As It Approaches Full Health

Courtesy of Benzinga.

Jefferies Downgrades Tenet As It Approaches Full Health

Tenet Healthcare Corp (NYSE: THC) shares are up 128 percent year-to-date, reflecting cost-cutting efforts and earnings stabilization. But given the firm’s gains in top-line growth and multiple expansion, Jefferies expects the rally to come to an end. 

The Rating

Analyst Brian Tanquilut downgraded Tenet from Buy to Hold and raised the price target from $28 to $38.

The Thesis

By Jefferies calculations, Tenet’s valuation relative to 2019 estimates for earnings before interest, tax, depreciation and amortization is about right for the firm’s growth prospects.

“Meaningful upside now hinges mostly on the monetization of Conifer at a valuation above 10-times EBITDA,” Tanquilut said in a Friday note. 

The potential sale of Conifer could deleverage Tenet’s debt, but not enough to drive significant near-term multiple expansion, the analyst said. 

At the same time, Jefferies expects that any long-term EBITDA growth depends on 2-percent volume growth in Tenet’s hospitals — a rate achieved only twice in the last three years. The hospital industry isn’t seen to achieve meaningful volume growth as increasing patient out-of-pocket costs stunt health care services.

“The growth acceleration needed to drive multiple expansion seems unlikely given sector headwinds,” Tanquilut said.

Price Action

Tenet shares were trading down more than 3 percent at $33.54 at the time of publication Friday.

Related Links:

Morgan Stanley: Health Care M&A Means Headwinds For Hospitals

Insurance Adjustment: Molina Healthcare Downgraded By JPMorgan On Valuation

Latest Ratings for THC

Date Firm Action From To
Jun 2018 Jefferies Downgrades Buy Hold
May 2018 Citigroup Maintains Buy Buy
May 2018 Credit Suisse Maintains Neutral Neutral

View More Analyst Ratings for THC


View the Latest Analyst Ratings

Posted-In: Brian Tanquilut JefferiesAnalyst Color Downgrades Health Care Price Target Analyst Ratings General Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!